Simvastatin

HMG-CoA reductase inhibitor Statin (lipid-lowering agent)

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO 5-20 mg/dog (or 0.5-2 mg/kg) q24h Duration: Long-term; reassess at 4-6 weeks
Notes: Start with lowest dose; titrate based on lipid panel. Administer with food to reduce GI upset. Use with caution in dogs with hepatic disease.
Cat PO 2.5-5 mg/cat (or 0.5-1 mg/kg) q24h Duration: Long-term; reassess at 4-6 weeks
Notes: Cats are sensitive to statins; use lowest effective dose. Monitor for anorexia and hepatotoxicity.
Horse PO 0.5-1 mg/kg q24h Duration: Long-term; reassess at 4-6 weeks
Notes: Limited data; use with caution. Monitor for muscle toxicity.
Cattle PO Not established; experimental use only Not established Duration: Not established
Notes: Not recommended for routine use; no withdrawal times established.
Small Ruminants PO Not established; experimental use only Not established Duration: Not established
Notes: Not recommended for routine use; no withdrawal times established.
Rabbit PO Not established; experimental use only Not established Duration: Not established
Notes: Not recommended for routine use.
Bird/Poultry PO Not established; experimental use only Not established Duration: Not established
Notes: Not recommended for routine use.
Exotic/Other PO Not established; experimental use only Not established Duration: Not established
Notes: Not recommended for routine use.

Clinical Indications & Species Uses

General Indications
  • Hyperlipidemia (hypercholesterolemia and hypertriglyceridemia) in dogs and cats
  • Atherosclerosis prevention (rare in animals)
  • Potential anti-inflammatory effects
Dog (Canine)
  • Hyperlipidemia (primary and secondary)
  • Hypercholesterolemia
  • Hypertriglyceridemia (when refractory to diet and other therapy)
  • Adjunct in management of atherosclerosis (rare)
  • Potential use for protein-losing nephropathy (to reduce proteinuria)
Cat (Feline)
  • Hyperlipidemia (especially hyperchylomicronemia)
  • Hypercholesterolemia
  • Hepatic lipidosis (adjunctive therapy, though not first-line)
Horse (Equine)
  • Hyperlipidemia (especially in ponies and miniature horses)
  • Hypertriglyceridemia
  • Equine metabolic syndrome (potential adjunctive therapy)

Pharmacology & Mechanism of Action

Drug Class: HMG-CoA reductase inhibitor | Pharmacological Group: Statin (lipid-lowering agent)

Mechanism of Action: Simvastatin is a prodrug that is hydrolyzed in the liver to its active β-hydroxy acid form. It competitively inhibits 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis. This reduces intracellular cholesterol levels, leading to upregulation of low-density lipoprotein (LDL) receptors on hepatocyte membranes, enhancing clearance of LDL from the circulation. It also modestly reduces very-low-density lipoprotein (VLDL) and triglycerides while increasing high-density lipoprotein (HDL) cholesterol.

Pharmacodynamics: Simvastatin lowers total cholesterol, LDL cholesterol, and triglycerides, and increases HDL cholesterol. In veterinary species, the lipid-lowering effects are less pronounced than in humans, and the drug is primarily used for its anti-inflammatory and endothelial-stabilizing properties. It may reduce C-reactive protein and improve vascular function. The onset of lipid-lowering effect is gradual, with maximal effect seen after several weeks of therapy.

⚡ Pharmacokinetics Summary

Absorption: In humans, simvastatin is well absorbed orally, but undergoes extensive first-pass metabolism in the liver, resulting in low systemic bioavailability. In dogs, oral bioavailability is approximately 5-10%. Food increases absorption, but the clinical significance in animals is not well established.
Distribution: Simvastatin is highly protein-bound (approximately 95%) in plasma. It distributes widely into tissues, with highest concentrations in the liver, where it exerts its primary effect. It crosses the blood-brain barrier to a limited extent and is excreted in milk in small amounts.
Metabolism: Simvastatin is extensively metabolized in the liver, primarily by cytochrome P450 3A4 (CYP3A4) to active and inactive metabolites. The active β-hydroxy acid metabolite is responsible for the pharmacological activity. Metabolism is species-dependent, with dogs and cats showing similar pathways but different rates.
Excretion: Simvastatin and its metabolites are primarily excreted in the feces (about 60%) via biliary excretion, with about 13% excreted in the urine. Enterohepatic recirculation occurs. In animals, the elimination half-life is short, but the pharmacodynamic effect lasts longer due to the irreversible inhibition of HMG-CoA reductase.
Half-Life: Dog: approximately 2-3 hours; Cat: approximately 1-2 hours; Horse: not well documented, but likely similar to other species.
Bioavailability: Low systemic bioavailability due to extensive first-pass metabolism; in dogs, oral bioavailability is approximately 5-10%.
Protein Binding: Approximately 95% protein-bound in plasma.

Available Formulations & Strengths

Oral Tablet 5 mg, 10 mg, 20 mg, 40 mg, 80 mg (PO)
Oral Suspension (compounded) Various (e.g., 10 mg/mL) (PO)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to simvastatin or any component
  • Active liver disease or unexplained persistent elevations in serum transaminases
  • Pregnancy and lactation (in animals, safety not established; contraindicated in pregnant animals due to potential teratogenic effects)
  • Concurrent use of strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, erythromycin, clarithromycin, cyclosporine) due to increased risk of myopathy
  • Severe renal impairment (use with caution)
Warnings & Clinical Precautions:
  • Use with caution in animals with hepatic disease; monitor liver enzymes periodically.
  • Use with caution in animals with a history of myopathy or rhabdomyolysis.
  • Discontinue if unexplained muscle pain, tenderness, or weakness occurs, especially if accompanied by malaise or fever.
  • Cats may be more sensitive to adverse effects; monitor for anorexia and weight loss.
  • Not approved for use in food animals; extra-label use requires careful consideration of withdrawal times.
  • May cause gastrointestinal upset; administer with food.
  • Safety in breeding, pregnant, or lactating animals has not been established.
  • Do not use in animals with active hepatic disease or unexplained persistent transaminase elevations.

Adverse Effects & Reactions

Common:

  • Gastrointestinal signs (vomiting, diarrhea, anorexia)
  • Elevated liver enzymes (ALT, AST)
  • Elevated creatine kinase (CK)

Serious / Severe:

  • Myopathy/rhabdomyolysis (rare but serious)
  • Hepatotoxicity (rare)
  • Acute pancreatitis (rare)

Rare:

  • Peripheral neuropathy
  • Immune-mediated necrotizing myopathy
  • Interstitial lung disease (in humans; not reported in animals)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin, cyclosporine) Increased plasma levels of simvastatin, increasing risk of myopathy and rhabdomyolysis. High
Fibrates (e.g., gemfibrozil, fenofibrate) Increased risk of myopathy and rhabdomyolysis. High
Niacin (nicotinic acid) Increased risk of myopathy and rhabdomyolysis. Moderate
Warfarin and other anticoagulants Simvastatin may potentiate the anticoagulant effect; monitor prothrombin time. Moderate
Digoxin Simvastatin may slightly increase digoxin levels; monitor for digoxin toxicity. Mild
Colchicine Increased risk of myopathy. Moderate

Overdose & Toxicity Management

Signs of Toxicity:

  • Gastrointestinal upset (vomiting, diarrhea)
  • Lethargy
  • Muscle weakness or pain
  • Elevated liver enzymes
  • Elevated CK
  • In severe cases, rhabdomyolysis and acute renal failure

Emergency Treatment Protocol: There is no specific antidote. Treatment is symptomatic and supportive. Induce emesis if ingestion is recent (within 1-2 hours) and the animal is conscious. Administer activated charcoal to reduce absorption. Provide intravenous fluids to maintain renal perfusion. Monitor liver enzymes, CK, and renal function. In severe cases, consider hemodialysis (though simvastatin is highly protein-bound, so dialysis may not be effective).

Food Animal Withdrawal Times

Simvastatin is not approved for use in food animals. No withdrawal times have been established. If used extra-label in food animals, a prolonged withdrawal period (e.g., 30 days for meat and 7 days for milk) may be considered, but this is not based on scientific data. It is strongly recommended to avoid use in food animals.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F).

Light Sensitivity: Light-sensitive — protect from direct exposure.

Handling & Special Conditions: Protect from light and moisture. Keep in original container with desiccant. Do not remove desiccant from the bottle.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use.

Extra-Label (Off-Label) Use: Simvastatin is not FDA-approved for veterinary use. Use in animals is extra-label and must comply with AMDUCA (Animal Medicinal Drug Use Clarification Act) regulations. Extra-label use is permitted only by or on the order of a licensed veterinarian within a valid veterinarian-client-patient relationship. For food animals, extra-label use is prohibited if an approved animal drug exists that would be effective, and withdrawal times must be extended appropriately.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Simvastatin is a potent HMG-CoA reductase inhibitor used primarily for hyperlipidemia in dogs and cats. In veterinary medicine, its use is limited due to the relatively low incidence of atherosclerosis and the availability of other lipid-lowering agents (e.g., omega-3 fatty acids, fibrates). However, it may be beneficial in cases of severe hypercholesterolemia or hypertriglyceridemia that are refractory to dietary management. In dogs, it has been used experimentally to reduce proteinuria in protein-losing nephropathy. In cats, it should be used with caution due to increased sensitivity to adverse effects. In horses, it may be used for hyperlipidemia, especially in breeds prone to hypertriglyceridemia. The drug is not recommended for use in food animals due to lack of withdrawal data. Before initiating therapy, baseline liver enzymes and CK should be measured, and these should be monitored periodically during treatment. The drug should be discontinued if muscle toxicity or hepatotoxicity is suspected. Because of the risk of drug interactions, a thorough medication history is essential. Simvastatin is a prodrug and requires hepatic metabolism; therefore, hepatic function should be assessed. In animals with hepatic disease, alternative lipid-lowering agents may be preferred. Overall, simvastatin can be a valuable tool in managing dyslipidemia in companion animals when used judiciously and with appropriate monitoring.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)